![](https://www.regulatorypharmanet.com/wp-content/uploads/2021/06/france.png)
ACT EU: Launch of Two New Pilot Projects for Scientific Advice and Clinical Trials in Europe
The Accelerating Clinical Trials in the EU (ACT EU) initiative has launched two pilot projects aimed at improving the quality…
READ
The Accelerating Clinical Trials in the EU (ACT EU) initiative has launched two pilot projects aimed at improving the quality…
READ
The Certificate of Pharmaceutical Product (CPP) is a document issued by a country’s regulatory authority at the request of a…
READ
The National Coordination Center for Ethical Committees (CCNCE) report highlights critical issues and recommendations for Italy’s 40 Territorial Ethical Committees…
READ
Over the past few years, the use of Artificial Intelligence (AI) in pharmaceutical industry is rapidly expanding. AI is a…
READ
Legacy devices are those that were approved under the previous MDD but are still in use or available on the…
READ
The transparency of transfers of value declared by pharmaceutical companies is crucial for maintaining trust and integrity within the healthcare…
READ
The European Medicines Agency (EMA) has recently published a significant update to its guideline on Environmental Risk Assessment (ERA) for…
READ
The regulation detailing the organization and functioning of the Scientific-Economic Commission of Pharmaceuticals (CSE) of the Italian Medicines Agency (AIFA)…
READ
The transition of clinical trial applications from the Directive 2001/20/EC (CTD) to the Regulation EU No 536/2014 (CTR), facilitated by…
READ
According to GVP (Good Pharmacovigilance Practices) Module VI, MAHs are required to conduct actively global literature searches at least once…
READ